Phase II study of tacrolimus and methotrexate for prophylaxis of acute graft-versus-host disease after HLA-A, B, and DRB1 genotypically mismatched unrelated bone marrow transplantation among Japanese patients

Tetsuya Nishida, Tohru Murayama, Hisamaru Hirai, Shinichiro Okamoto, Hiroshi Sao, Masamichi Hara, Heiwa Kanamori, Yoshiko Atsuta, Keitaro Matsuo, Yasuo Morishima, Yoshihisa Kodera

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Bone marrow transplantation from unrelated donors (UR-BMT) has been considered to be effective for patients with hematological malignancies who have no suitable related donor. However, disparities of HLA between a recipient and a donor increase the risk of severe acute graft-versus-host disease (GVHD). We evaluated GVHD prophylaxis using tacrolimus and methotrexate for HLA-A, B, or DRB1 genotypically mismatched UR-BMT. Fifty-five patients were enrolled in this study. The incidence of grade III to IV acute GVHD was 23.6% for all patients. No significant difference in the incidence of grade III to IV acute GVHD was observed between HLA-A or B 1 locus mismatch transplantation (18.8%) and HLA-DRB1 1 locus mismatch transplantation (16.7%) (P = 0.96). The incidence of chronic GVHD was 71.7%. Disease-free survival at 5 years was 53.2% for patients with standard risk disease and 24.5% for patients with high-risk disease. Patients with chronic GVHD exhibited better disease-free survival than those without chronic GVHD (53.2 vs. 30.9%, P = 0.011). Twenty patients (36.4%) had a relapse of leukemia and 14 of them died of recurrent leukemia. This study indicates tacrolimus and methotrexate can lower the risk of severe acute GVHD after HLA-A, B, or DRB1 genotypically 1 locus mismatched UR-BMT.

Original languageEnglish
Pages (from-to)98-105
Number of pages8
JournalInternational Journal of Hematology
Volume89
Issue number1
DOIs
Publication statusPublished - 2009 Jan

Fingerprint

HLA-DRB1 Chains
HLA-A Antigens
HLA-B Antigens
Tacrolimus
Graft vs Host Disease
Bone Marrow Transplantation
Methotrexate
Disease-Free Survival
Incidence
Leukemia
Transplantation
Tissue Donors
Unrelated Donors
Hematologic Neoplasms
Recurrence

Keywords

  • GVHD prophylaxis
  • HLA mismatched UR-BMT
  • Tacrolimus

ASJC Scopus subject areas

  • Hematology

Cite this

Phase II study of tacrolimus and methotrexate for prophylaxis of acute graft-versus-host disease after HLA-A, B, and DRB1 genotypically mismatched unrelated bone marrow transplantation among Japanese patients. / Nishida, Tetsuya; Murayama, Tohru; Hirai, Hisamaru; Okamoto, Shinichiro; Sao, Hiroshi; Hara, Masamichi; Kanamori, Heiwa; Atsuta, Yoshiko; Matsuo, Keitaro; Morishima, Yasuo; Kodera, Yoshihisa.

In: International Journal of Hematology, Vol. 89, No. 1, 01.2009, p. 98-105.

Research output: Contribution to journalArticle

Nishida, Tetsuya ; Murayama, Tohru ; Hirai, Hisamaru ; Okamoto, Shinichiro ; Sao, Hiroshi ; Hara, Masamichi ; Kanamori, Heiwa ; Atsuta, Yoshiko ; Matsuo, Keitaro ; Morishima, Yasuo ; Kodera, Yoshihisa. / Phase II study of tacrolimus and methotrexate for prophylaxis of acute graft-versus-host disease after HLA-A, B, and DRB1 genotypically mismatched unrelated bone marrow transplantation among Japanese patients. In: International Journal of Hematology. 2009 ; Vol. 89, No. 1. pp. 98-105.
@article{e5b1b9d56e4c4b8797573ef346c2ae3f,
title = "Phase II study of tacrolimus and methotrexate for prophylaxis of acute graft-versus-host disease after HLA-A, B, and DRB1 genotypically mismatched unrelated bone marrow transplantation among Japanese patients",
abstract = "Bone marrow transplantation from unrelated donors (UR-BMT) has been considered to be effective for patients with hematological malignancies who have no suitable related donor. However, disparities of HLA between a recipient and a donor increase the risk of severe acute graft-versus-host disease (GVHD). We evaluated GVHD prophylaxis using tacrolimus and methotrexate for HLA-A, B, or DRB1 genotypically mismatched UR-BMT. Fifty-five patients were enrolled in this study. The incidence of grade III to IV acute GVHD was 23.6{\%} for all patients. No significant difference in the incidence of grade III to IV acute GVHD was observed between HLA-A or B 1 locus mismatch transplantation (18.8{\%}) and HLA-DRB1 1 locus mismatch transplantation (16.7{\%}) (P = 0.96). The incidence of chronic GVHD was 71.7{\%}. Disease-free survival at 5 years was 53.2{\%} for patients with standard risk disease and 24.5{\%} for patients with high-risk disease. Patients with chronic GVHD exhibited better disease-free survival than those without chronic GVHD (53.2 vs. 30.9{\%}, P = 0.011). Twenty patients (36.4{\%}) had a relapse of leukemia and 14 of them died of recurrent leukemia. This study indicates tacrolimus and methotrexate can lower the risk of severe acute GVHD after HLA-A, B, or DRB1 genotypically 1 locus mismatched UR-BMT.",
keywords = "GVHD prophylaxis, HLA mismatched UR-BMT, Tacrolimus",
author = "Tetsuya Nishida and Tohru Murayama and Hisamaru Hirai and Shinichiro Okamoto and Hiroshi Sao and Masamichi Hara and Heiwa Kanamori and Yoshiko Atsuta and Keitaro Matsuo and Yasuo Morishima and Yoshihisa Kodera",
year = "2009",
month = "1",
doi = "10.1007/s12185-008-0219-8",
language = "English",
volume = "89",
pages = "98--105",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Phase II study of tacrolimus and methotrexate for prophylaxis of acute graft-versus-host disease after HLA-A, B, and DRB1 genotypically mismatched unrelated bone marrow transplantation among Japanese patients

AU - Nishida, Tetsuya

AU - Murayama, Tohru

AU - Hirai, Hisamaru

AU - Okamoto, Shinichiro

AU - Sao, Hiroshi

AU - Hara, Masamichi

AU - Kanamori, Heiwa

AU - Atsuta, Yoshiko

AU - Matsuo, Keitaro

AU - Morishima, Yasuo

AU - Kodera, Yoshihisa

PY - 2009/1

Y1 - 2009/1

N2 - Bone marrow transplantation from unrelated donors (UR-BMT) has been considered to be effective for patients with hematological malignancies who have no suitable related donor. However, disparities of HLA between a recipient and a donor increase the risk of severe acute graft-versus-host disease (GVHD). We evaluated GVHD prophylaxis using tacrolimus and methotrexate for HLA-A, B, or DRB1 genotypically mismatched UR-BMT. Fifty-five patients were enrolled in this study. The incidence of grade III to IV acute GVHD was 23.6% for all patients. No significant difference in the incidence of grade III to IV acute GVHD was observed between HLA-A or B 1 locus mismatch transplantation (18.8%) and HLA-DRB1 1 locus mismatch transplantation (16.7%) (P = 0.96). The incidence of chronic GVHD was 71.7%. Disease-free survival at 5 years was 53.2% for patients with standard risk disease and 24.5% for patients with high-risk disease. Patients with chronic GVHD exhibited better disease-free survival than those without chronic GVHD (53.2 vs. 30.9%, P = 0.011). Twenty patients (36.4%) had a relapse of leukemia and 14 of them died of recurrent leukemia. This study indicates tacrolimus and methotrexate can lower the risk of severe acute GVHD after HLA-A, B, or DRB1 genotypically 1 locus mismatched UR-BMT.

AB - Bone marrow transplantation from unrelated donors (UR-BMT) has been considered to be effective for patients with hematological malignancies who have no suitable related donor. However, disparities of HLA between a recipient and a donor increase the risk of severe acute graft-versus-host disease (GVHD). We evaluated GVHD prophylaxis using tacrolimus and methotrexate for HLA-A, B, or DRB1 genotypically mismatched UR-BMT. Fifty-five patients were enrolled in this study. The incidence of grade III to IV acute GVHD was 23.6% for all patients. No significant difference in the incidence of grade III to IV acute GVHD was observed between HLA-A or B 1 locus mismatch transplantation (18.8%) and HLA-DRB1 1 locus mismatch transplantation (16.7%) (P = 0.96). The incidence of chronic GVHD was 71.7%. Disease-free survival at 5 years was 53.2% for patients with standard risk disease and 24.5% for patients with high-risk disease. Patients with chronic GVHD exhibited better disease-free survival than those without chronic GVHD (53.2 vs. 30.9%, P = 0.011). Twenty patients (36.4%) had a relapse of leukemia and 14 of them died of recurrent leukemia. This study indicates tacrolimus and methotrexate can lower the risk of severe acute GVHD after HLA-A, B, or DRB1 genotypically 1 locus mismatched UR-BMT.

KW - GVHD prophylaxis

KW - HLA mismatched UR-BMT

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=67349206666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349206666&partnerID=8YFLogxK

U2 - 10.1007/s12185-008-0219-8

DO - 10.1007/s12185-008-0219-8

M3 - Article

C2 - 19052693

AN - SCOPUS:67349206666

VL - 89

SP - 98

EP - 105

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 1

ER -